Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Two of a kind: China's first pet cloning service duplicates star pooch

Published 12/17/2018, 06:46 AM
Updated 12/17/2018, 06:46 AM
© Reuters. Screen displays the microscopic image of an attempt to inseminate a dog egg at a lab of the biotech company Sinogene that specialises in dog cloning in Beijing

© Reuters. Screen displays the microscopic image of an attempt to inseminate a dog egg at a lab of the biotech company Sinogene that specialises in dog cloning in Beijing

By Joseph Campbell

BEIJING (Reuters) - Juice is a one-foot tall canine wonder who has starred in dozens of Chinese film and television productions.

As he gets older and his illustrious career peaks, his Beijing-based master has one wish for the mutt - to live on. Maybe forever.

A mongrel stray adopted off the streets, the nine year-old Juice -- or "Guozhi" in Mandarin -- is unable to reproduce since he was neutered from an early age. But his master, animal trainer He Jun, wants to continue his star pooch's image by making a genetic clone.

"Juice himself is a piece of intellectual property with social influence," said He.

To achieve that, He went to Sinogene, China's first biotech company to provide pet cloning services. Sinogene made headlines when it successfully cloned a gene-edited beagle in May last year. A month later, it launched commercial cloning services.

For at least 380,000 yuan ($55,065), pet owners can clone their pets.

Sinogene's CEO Mi Jidong said the company's pet cloning business is in its initial stages, but he plans to expand services to eventually include gene editing.

"We've discovered that more and more pet owners want their pets to accompany them for an even longer period of time," said Mi.

China's biotech industry is growing rapidly and, compared with similar enterprises in the West, faces relatively few regulatory barriers.

Earlier this year, a Shanghai lab produced the world's first monkey clones, two long-tailed macaques. More controversially, He Jiankui of China's Southern (NYSE:SO) University of Science and Technology last month claimed he used gene-editing technology to alter the embryonic genes of twin girls.

Tin-Lap Lee, an associate professor of biomedical sciences at the Chinese University of Hong Kong, said while China has regulations on the use of animals for lab research, there are no laws explicitly covering animal cloning.

"On the government side, the image of this cloning industry is very high-tech, and definitely...is very supportive of those high-tech industries because of their high-profit margin," said Lee.

In Juice's case, skin samples were collected from the dog's lower abdomen and within weeks, Sinogene was able to isolate his DNA and fertilize an egg.

The fertilized egg is then surgically inserted into the uterus of a surrogate mother dog - in this case a beagle.

Juice's copy, "Little Juice" -- or "Zhizhi" in Chinese -- was born in mid-September and stayed with its surrogate mother in Sinogene's lab for about a month. The puppy was later given to He at a small ceremony at which the original Juice was present.

While He has not committed Little Juice to show business just yet, he sees lots of potential.

© Reuters. Screen displays the microscopic image of an attempt to inseminate a dog egg at a lab of the biotech company Sinogene that specialises in dog cloning in Beijing

"We believe he'll be even better than the older Juice," He said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.